Recursion Pharmaceuticals, Inc.
RXRX
$5.68
-$0.27-4.54%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -574.78M | -463.66M | -377.75M | -374.93M | -354.11M |
| Total Depreciation and Amortization | 48.45M | 36.49M | 31.10M | 31.48M | 28.05M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 144.90M | 105.99M | 84.15M | 74.38M | 71.60M |
| Change in Net Operating Assets | -7.40M | -38.00M | -55.32M | -62.45M | -62.30M |
| Cash from Operations | -388.83M | -359.17M | -317.82M | -331.52M | -316.76M |
| Capital Expenditure | -8.87M | -13.70M | -14.46M | -10.65M | -13.43M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 277.10M | 277.10M | -71.00K | -71.00K | 1.84M |
| Divestitures | -4.44M | -- | -- | -- | -- |
| Other Investing Activities | -4.35M | -3.35M | -3.35M | -2.95M | 48.00K |
| Cash from Investing | 259.44M | 260.06M | -17.89M | -13.67M | -11.54M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.46M | -4.44M | -3.03M | -770.00K | -768.00K |
| Issuance of Common Stock | 337.21M | 308.56M | 377.17M | 412.21M | 152.88M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 330.75M | 304.12M | 374.14M | 411.44M | 152.11M |
| Foreign Exchange rate Adjustments | 1.65M | -3.41M | 190.00K | -328.00K | -29.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 203.01M | 201.60M | 38.62M | 65.93M | -176.23M |